Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07290413 · ClinicalTrials.gov registry record · Phase 2
Photobiomodulation for the Prevention of Oral Mucositis
A Phase 2 study of Oral Mucositis, sponsored by Brigham and Women's Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
- 1
- Study location
NCT07290413: Active Phase 2 study of Oral Mucositis, sponsored by Brigham and Women's Hospital.
NCT07290413 is a Phase 2 study of Oral Mucositis that is active but no longer recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 78 participants, below the 100-participant average among 10 other Oral Mucositis trials with a reported enrollment target (22% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07290413, a Phase 2 study of Oral Mucositis, is active but no longer recruiting, sponsored by Brigham and Women's Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if photobiomodulation works to prevent severe oral mucositis in patients who are undergoing allogeneic hematopoietic cell transplantation. The main questions it aims to answer are: Does 1) intraoral , 2) extraoral, or 3) combined intraoral/extraoral photobiomodulation have optimal prevention/therapeutic effect in prevention of oral mucositis in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation (alloHSCT). Participants will: Be randomized to one of the three treatment arms Receive daily photobiomodulation therapy (from beginning of transplant conditioning through Day +20 after transplantation) Be evaluated for oral mucositis and symptoms daily Visit the clinic once every 2 weeks for checkups and tests Keep a diary of their symptoms and the number of times they use a rescue inhaler
Primary Outcome
WHO Score (0-4, "severe" defined as grades 3 and 4)
Conditions Studied
Interventions
- DEVICE Photobiomodulation - INTRAORAL
- DEVICE Photobiomodulation - EXTRAORAL
- DEVICE Photobiomodulation - INTRAORAL and EXTRAORAL
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2025-12-01 |
| Est. Completion | 2027-05 |
| Phase | Phase 2 |
What the registry record for NCT07290413 still lists
NCT07290413 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 100-participant average among 10 other Oral Mucositis trials with a reported enrollment target (22% lower).
The record links to 1 condition, with Oral Mucositis appearing as the primary indexed condition, and to 3 interventions - of which Photobiomodulation - INTRAORAL is the first listed.
NCT07290413 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07290413 about?
NCT07290413 is a clinical study titled "Photobiomodulation for the Prevention of Oral Mucositis". The goal of this clinical trial is to learn if photobiomodulation works to prevent severe oral mucositis in patients who are undergoing allogeneic hematopoietic cell transplantation. The main questions it aims to answer are: Does 1) intraoral , 2) extraoral, or 3) combined intraoral/extraoral photo...
What is the current status of trial NCT07290413?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2025-12-01. Estimated completion is 2027-05.
What conditions does trial NCT07290413 study?
This clinical trial studies the following conditions: Oral Mucositis.
What interventions are being tested in trial NCT07290413?
The interventions under investigation include: Photobiomodulation - INTRAORAL (DEVICE), Photobiomodulation - EXTRAORAL (DEVICE), Photobiomodulation - INTRAORAL and EXTRAORAL (DEVICE).
Who is sponsoring clinical trial NCT07290413?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07290413 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oral Mucositis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07290413's enrollment target sits among peer trials
78 6th of 10 higher than 5 of 10 other Oral Mucositis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Oral Mucositis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Coconut Oil to Prevent Mouth Sores in Pediatric Patients Receiving High Dose Chemotherapy
RECRUITING · Phase 2
-
RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer
RECRUITING · Phase 2
-
MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients
ACTIVE NOT RECRUITING · Phase 2
-
Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus
COMPLETED · Phase 2
-
Safety and Efficacy of IZN-6N4 Oral Rinse for the Prevention of Oral Mucositis in Patients With Head and Neck Cancer
COMPLETED · Phase 2
-
Intraoral Photobiomodulation Therapy to Prevent Oral Mucositis in Patients Undergoing Hematopoietic Cell Transplantation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI